The HPV 9-10 Trial: Early Initiation of HPV Vaccination
Trial Parameters
Brief Summary
Every year, thousands of Americans die from cancers related to human papillomavirus (HPV). The vast majority of those deaths could be prevented with a safe and effective vaccine, yet many parents choose not have their children vaccinated when it is recommended at age 11 or 12. In this study, we will examine in a randomized trial whether earlier initiation of the vaccine at age 9-10 years will result in less parental refusal and higher rates of full vaccination at younger ages, before early sexual activity begins.
Eligibility Criteria
Practices: Inclusion Criteria: * Practices in Metro Denver, Colorado and Metro Los Angeles, California (specifically UCLA medical clinics and clinics affiliated with Children's Hospital of Orange County) * Practices that have at least 60% of providers agree to participate * Practices do not currently recommend HPV at 9-10 years. * Practice must have at least 100 eligible patients age 9-13 years Exclusion Criteria: * Practices with less than 100 eligible patients age 9-13 years * Practices currently routinely recommend HPV vaccine at 9-10 years. * Practices where less than 60% of providers agree to participate in the study. Patient Eligibility Criteria * Patient age 9-13 years * Seen at a participating practice in the last 3 years * Due for at least 1 dose of HPV vaccine